Alerts
Other content recommended for you
- Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
- Potential for epistemic injustice in evidence-based healthcare policy and guidance
- Justice and procedure: how does “accountability for reasonableness” result in fair limit-setting decisions?
- The ethical canary: narrow reflective equilibrium as a source of moral justification in healthcare priority-setting
- Value assessment frameworks: who is valuing the care in healthcare?
- NICE rejects trastuzumab emtansine for use on NHS
- NICE and the Cancer Drugs Fund—2020 vision?
- Cancer drugs: high price, uncertain value
- Most drugs paid for by £1.27bn Cancer Drugs Fund had no “meaningful benefit”
- How should we assess the clinical and cost effectiveness of histology independent cancer drugs?